Testing two immune therapy approaches for recurrent endometrial cancer

Plain-English translation of NCT05112601 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial compares two treatment approaches for people whose endometrial cancer has come back after prior treatment. One group receives and together—two medications that help your immune system fight cancer. The other group receives alone. Researchers want to see which approach helps people live longer without their cancer growing.

Standard chemotherapy doesn't work well for everyone with recurrent endometrial cancer, especially when the cancer has specific genetic changes. This medication approach works differently by activating your own immune system to attack cancer cells, and researchers want to know if using two of these immune medications together is more effective than using one alone.

Do you qualify?

You likely qualify if…

you have been diagnosed with endometrial cancer that has come back after previous treatment
your cancer has specific genetic features (a deficient mismatch repair system) confirmed by laboratory testing
you have measurable disease visible on imaging scans, or smaller amounts of detectable disease
you have received no more than two prior rounds of systemic therapy
if you previously received immune checkpoint therapy, you must have had a complete response and been disease-free for at least 12 months before the cancer returned

You likely don't qualify if…

you have active, untreated cancer in your brain or central nervous system
you have a severe autoimmune disease or are taking medications that suppress your immune system
you are pregnant, breastfeeding, or unable to use effective birth control during treatment
you have had a severe allergic reaction to nivolumab, ipilimumab, or similar medications
you have severe organ damage or other serious medical conditions that would make these medications unsafe for you

What participation looks like

You will be randomly assigned to receive either the combination of two medications or one medication given through an IV infusion every three weeks for up to eight cycles, then every four weeks after that. You'll visit the clinic regularly for infusions, blood tests, and imaging scans to monitor how the cancer responds. If your cancer disappears completely, you may continue the medication for up to 12 more months. Throughout the trial, you may have optional blood or tissue samples collected to help researchers understand how the treatment works.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Testing two immune therapy approaches for recurrent endometrial cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(137 sites)